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Abstract
Vascular endothelial growth factor C (VEGF-C) is a key mediator of lymphangiogenesis, acting via its receptors VEGF-R2 and
VEGF-R3. High expression of VEGF-C in tumors correlates with increased lymphatic vessel density, lymphatic vessel invasion,
sentinel lymph node metastasis and poor prognosis. Recently, we found that in a chemically induced skin carcinoma model,
increased VEGF-C drainage from the tumor enhanced lymphangiogenesis in the sentinel lymph node and facilitated
metastatic spread of cancer cells via the lymphatics. Hence, interference with the VEGF-C/VEGF-R3 axis holds promise to
block metastatic spread, as recently shown by use of a neutralizing anti-VEGF-R3 antibody and a soluble VEGF-R3 (VEGF-C/D
trap). By antibody phage-display, we have developed a human monoclonal antibody fragment (single-chain Fragment
variable, scFv) that binds with high specificity and affinity to the fully processed mature form of human VEGF-C. The scFv
binds to an epitope on VEGF-C that is important for receptor binding, since binding of the scFv to VEGF-C dose-
dependently inhibits the binding of VEGF-C to VEGF-R2 and VEGF-R3 as shown by BIAcore and ELISA analyses. Interestingly,
the variable heavy domain (VH) of the anti-VEGF-C scFv, which contains a mutation typical for camelid heavy chain-only
antibodies, is sufficient for binding VEGF-C. This reduced the size of the potentially VEGF-C-blocking antibody fragment to
only 14.6 kDa. Anti-VEGF-C VH-based immunoproteins hold promise to block the lymphangiogenic activity of VEGF-C, which
would present a significant advance in inhibiting lymphatic-based metastatic spread of certain cancer types.
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Introduction
Lymphangiogenesis is the growth of lymphatic vessels from
preexisting ones and the extent of lymphangiogenesis in cancers
such as malignant melanoma has been shown to be a predictor of
disease progression and survival [1]. The growth of peri- and
intratumoral lymphatic vessels, which, in contrary to blood vessels,
lack a basement membrane as well as coverage by smooth muscle
cells and pericytes and are therefore especially easy to be infiltrated
by cancer cells, opens up new ways for metastatic dissemination of
the primary tumor. Tumors control the growth of blood and
lymphatic vessels in their periphery by the secretion of growth
factors. Vascular endothelial growth factor-C (VEGF-C) has been
shown to be the main lymphangiogenic growth factor [2], together
with VEGF-D [3]. In many tumors, the expression of high levels of
VEGF-C has been correlated with lymphatic vessel invasion, the
emergence of sentinel and distant lymph node metastasis and
overall poor prognosis [4]. Today, tumor metastasis still represents
the hallmark of malignancy in cancer.
VEGF-C and VEGF-D exert their action via binding to VEGF-
receptors 2 and 3 [2,3]. While VEGF-R2 is expressed on blood and
lymphatic vascular endothelial cells, VEGF-R3 is in the adult
expressed normally onlylymphatic endothelial cells. Next to their role
in metastasis, VEGF-C and -D might alsodirectly activate VEGF-R3
expressed on tumor cells [5,6], leading to autocrine activation of
primary cancer growth and a more aggressive cancer phenotype.
VEGF-C and -D are therefore attractive targets for cancer
therapy and agents that are capable of blocking VEGF-C/D and
reducing cancer aggressiveness and metastatic dissemination are
highly needed to prevent disease progression. Interference with the
VEGF-C/D – VEGF-R2/3 system has shown promising results in
reducing tumor metastasis and/or primary tumor growth in a
number of models. Notably, blocking of VEGF-D by a mouse
monoclonal anti-human-VEGF-D antibody [7,8] was effective in
halting primary tumor growth and suppressing local tumor
metastasis in a mouse xenograft tumor model. Similarly,
neutralizing antibodies against VEGF-R3 inhibited lymph node
metastasis [9–11] and soluble VEGF-R3, that traps both VEGF-C
and VEGF-D, blocked lymphangiogenesis and lymph node
metastasis in several models [12,13].
However, these strategies have potential drawbacks since
VEGF-D and VEGF-R3 function in other cells and tissues may
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where it controls bone growth via VEGF-R3 [14]. Blocking of
either of these molecules could potentially lead to undesired side
effects on bone regeneration.
Blocking of VEGF-C by antibodies has been reported in only a
few studies [15–18], none of which involved tumor studies.
Furthermore, none of these antibodies are of human origin, which
hampers their use in human therapy due to immunogenicity. To
directly obtain human antibodies, antibody phage-display libraries
based on human germline antibody genes offer an alternative
route. The fully human ETH-2 Gold antibody phage-display
library has been used to isolate binders against a wide spectrum of
antigens [19], and antibodies based on binders isolated from the
library (e.g. L19, a fully human IgG against the extra domain B of
fibronectin, a vascular tumor neo-angiogenesis marker) are
currently under clinical development [20].
VEGF-C undergoes excessive processing by proprotein con-
vertases before and after secretion; this processing trims the full
length VEGF-C by a N-terminal and C-terminal propeptide and
generates ultimately the fully processed, mature DNDC-VEGF-C
[21]. This middle third domain contains the VEGF homology
domain (VHD), the region of highest homology between VEGF
family members and is the most active form of VEGF-C with
highest affinity to VEGF-R3, and the only form of VEGF-C that
also binds VEGF-R2 [22]. DNDC-VEGF-C therefore represents
the most interesting VEGF-C variant to block.
In this study, we used the fully human ETH-2 Gold antibody
phage display library to identify antibody fragments specifically
binding to the fully processed, mature form of human VEGF-C,
DNDC-VEGF-C. We generated a panel of first and affinity
matured second-generation single-chain Fragment variable (scFv)
binders specifically binding to human DNDC-VEGF-C and were
able to show that these scFv block the binding of VEGF-C to both
VEGF-R2 and -3. Furthermore, we found that the variable heavy
domain (VH) of the anti-VEGF-C scFv is sufficient for binding to
DNDC-VEGF-C.
Results
Selection of anti-VEGF-C scFv
We employed the human fully synthetic ETH-2 Gold antibody
phage display library [19] to select for binders against P. pastoris-
derived human DNDC-VEGF-C (Figure 1). During the course of
the selection against VEGF-C, a 974-fold increase in the ratio of
output vs. input phage titers, expressed as the enrichment factor,
was observed from round 2 to round 3, while the mock selection
with uncoated immunotubes yielded a more than 30 times less
strong enrichment (Table 1). In the subsequent ELISA screening,
23 of 64 randomly picked clones from round 3 reacted against
DNDC-VEGF-C, while none of the randomly picked clones from
the 2
nd round of selection were positive (Figure 2A). Out of these
23 clones, 4 clones possessing unique amino acid (aa) sequences
were retrieved by sequencing. All 4 unique clones were from the
lambda subclass; 3 of these 4 clones (VC1, VC2 and VC3) showed
3 identical aa in the randomized complementarity determining
region 3 (CDR3) (1 identical aa out of 6 in CDR-L3 (CDR3 of the
light chain), 2 identical aa out of 4 in CDR-H3 (CDR3 of the
heavy chain)), while the fourth clone (VC4) had a completely
unrelated sequence (Table 2).
As the isoelectric point (pI) of P. pastoris-derived DNDC-VEGF-
C is 8.3 (as deduced from the amino acid sequence; however,
glycosylation also affects the pI), we decided to use 100 mM
Figure 1. Amino acid sequences of DNDC-VEGF-C and DNDC-VEGF-D variants used in the study. The region of 100% identity within used
DNDC-VEGF-C variants is shown within the black frame, the possible epitope regions of VC2.2.2 anti-VEGF-C scFv on DNDC-VEGF-C and the
corresponding regions on DNDC-VEGF-D are shown within grey frames. P.p, P. pastoris-derived DNDC-VEGF-C; R&D, commercially available
mammalian cell-derived DNDC-VEGF-C or DNDC-VEGF-D, respectively.
doi:10.1371/journal.pone.0011941.g001
Table 1. Enrichment factors during panning.
Antigen Round Input (tu) Output (tu) Ratio (out/in) Enrichment (ratio n/ratio n-1)
VEGF-C 1 5.0610
12 1.2610
6 2.4610
27 n/a
VEGF-C 2 5.4610
13 1.2610
4 2.2610
210 0.00093
VEGF-C 3 6.7610
13 1.5610
7 2.2610
27 974
mock 1 5.0610
12 5.0610
5 4.0610
28 n/a
mock 2 6.3610
13 4.0610
4 6.3610
210 0.016
mock 3 4.0610
13 8.0610
5 2.0610
28 32
Transducing units (tu) before and after panning rounds were determined using titration of transduced colonies. Ratio of output vs. input in the same round and
enrichment, i.e. the factor by which the ratio of rescued phages differed from round n-1 to round n was calculated. ‘‘Mock’’ refers to selections with uncoated
immunotubes.
doi:10.1371/journal.pone.0011941.t001
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is better suited for destabilizing the VEGF-C/phage complex.
Interestingly, a parallel panning with 100 mM TEA pH 12 as the
elution agent did not yield any binders after 4 rounds of panning.
Since the amino acid sequence of P. pastoris-derived DNDC-
VEGF-C and of mammalian cell-derived DNDC-VEGF-C differs
at the C- and N-terminal ends (Figure 1), all 4 clones were retested
on both antigens. The 3 clones with partial identity (VC1, VC2
and VC3) bound to an epitope present on both DNDC-VEGF-C
derived from P. pastoris and mammalian cells while the fourth,
unrelated clone (VC4), bound only to P. pastoris-derived DNDC-
VEGF-C but not to mammalian cell derived DNDC-VEGF-C
(Figure 2B), indicating that the epitopes for the scFvs VC1, VC2
and VC3 are different from the epitope recognized by scFv VC4.
After cleavage of the C- and N-terminal propeptides, both
VEGF-C and VEGF-D exist as the fully processed, mature DNDC
protein. This central VEGF homology domain (VHD) in VEGF-C
and VEGF-D is highly homologous (more than 50% identity and
more than 70% homology, Figure 1). However, clone VC2 did not
bind to mammalian cell-derived DNDC-VEGF-D, confirming the
specificity for VEGF-C (Figure 2C).
All 4 clones were next analyzed with surface plasmon resonance
(SPR) on a streptavidin coated BIAcore chip to which biotinylated
mammalian cell-derived DNDC-VEGF-C was immobilized. This
analysis revealed different binding profiles, and clone VC2 was
chosen to be used for affinity maturation since it displayed the best
apparent binding affinity for VEGF-C (Figure 2D).
Affinity maturation
Antibody phage libraries to be used in affinity maturation
selections were constructed essentially as described [23], based on
the amino acid sequence of clone VC2. Randomizations were
engineered in CDR1 of both heavy and light chains. The obtained
library consisted of 3.3610
6 clones, of which 14 randomly picked
clones all contained the scFv insert as assessed by colony PCR
analysis. More than 90% of 96 randomly picked clones were
capable of expressing a soluble scFv antibody fragment, as assessed
by Dot-Blot analysis (data not shown). Sequencing of 6 random
clones revealed completely randomized aa sequences in the
desired CDR-H1 and CDR-L1, while the VC2 parental aa
sequence was retained in all other residues (data not shown).
After 1 to 3 rounds of panning of this affinity maturation library
on varying concentrations of biotinylated P. pastoris and mamma-
lian cell-derived DNDC-VEGF-C, random clones from several
selections were analyzed by ELISA. This analysis showed that
more selection rounds and higher antigen concentration increased
the percentage and signal intensity of binders identified (Figure 3A
and 3B).
Table 2. Amino acid sequences of parental and affinity matured anti-VEGF-C scFv.
CDR-H1 FR2 CDR-H2 CDR-H3 CDR-L1 CDR-L3
Clone 31 32 33 44 45 64 95 96 97 98 99 100 31a 31b 32 91 92 93 94 95 96 Frequency of
recovery
Library S Y A G L K X X X X (X) (X) S Y Y X X X X X X NA
VC1 S Y A G P K ESSM -- S Y Y PI RW A P 17/64
VC2 S Y A E LK ESLP-- S Y Y PRFYP V 3/64
VC3 S Y A G L EE S L P -- S Y Y PGSER P 1/64
VC4 S Y A G L K WP A T G -SY Y VDAW P G 2/64
VC2.2.2 QNY EL K ESLP-- ENW PRFYP V N A
VC2.2.5 QNY EL K ESLP-- HSQ PRFYP V N A
VC2.1.5 KNY EL K ESLP-- KGW PRFYP V N A
VC2.1.20 QNY EL K ESLP-- KNN PRFYP V N A
VC2.2.4 QNY EL K ESLP-- SGN PRFYP V N A
VC2.2.1 KNA EL K ESLP-- NDY PRFYP V N A
VC2.2.7 GNY EL K ESLP-- KGY PRFYP V N A
VC2.2.3 NNY EL K ESLP-- QNT PRFYP V N A
VC2.1.6 SYA EL K ESLP-- SYY PRFYP V N A
VC2.1.26 NKY EL K ESLP-- AHM PRFYP V N A
VC2.2.13 QSL EL K ESLP-- QWK PRFYP V N A
Numbering according to Chothia et al. [43] VC1 to VC4, first generation anti-VEGF-C scFv; VC2.2.2 to VC2.1.6, positive anti-VEGF-C scFv clones from affinity maturation;
VC2.1.26, VC2.2.13, negative scFv clones from affinity maturation; X, random amino acid encoded in the CDR-3s of the ETH-2 Gold library.
doi:10.1371/journal.pone.0011941.t002
Figure 2. Binding specificities of anti-VEGF-C scFv. (A) ELISA screening of random clones obtained after 2 or 3 rounds of panning against
DNDC-VEGF-C. (B) ELISA analysis of representative anti-VEGF-C scFv clones for the 4 different amino acid sequences obtained. Maxisorp or
streptavidin-precoated (SA) plates were coated with his-tagged human DNDC-VEGF-C derived from P. pastoris or biotinylated his-tagged human
DNDC-VEGF-C from mammalian cells or P. pastoris, respectively. Control surfaces were left untreated. Antibody fragments and control antibodies
were subsequently added and the ELISA was developed as described in Materials and Methods. (C) Cross-reactivity tested by ELISA. Human DNDC-
VEGF-C orDNDC-VEGF-D (both from mammalian cells) were coated on a maxisorp plate. Anti-VEGF-C scFv clone VC2 or a negative control (PBS only)
was added and the ELISA was developed as described in Materials and Methods. (D) BIAcore profiles from the 4 different anti-VEGF-C scFv clones.
Different concentrations of protein-A purified scFv were injected on a streptavidin-precoated sensorchip coated with ca. 2000 RU biotinylated
mammalian cell-derived DNDC-VEGF-C.
doi:10.1371/journal.pone.0011941.g001
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PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e11941Figure 3. Affinity matured anti-VEGF-C scFvs possess a higher affinity. (A, B) ELISA analysis of bacterial supernatant from randomly picked
affinity matured clones after 1 to 3 rounds of selection on biotinylated (A) P. pastoris-derived or (B) mammalian cell-derived DNDC-VEGF-C. (C) BIAcore
profiles of monomeric affinity matured anti-VEGF-C scFvs. Monomeric fractions of protein-A purified scFv were prepared by FPLC and injected as 2-
fold dilution series on a streptavidin-sensorchip coated with 2000 RU biotinylated DNDC-VEGF-C derived from mammalian cells.
doi:10.1371/journal.pone.0011941.g003
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highest ELISA signals and of 2 negative controls was subsequently
performed. One clone (VC2.1.6) was identified to be identical to
the parental scFv VC2, and clones VC2.2.5 and VC2.1.11 were
identical to each other. The positive clones showed a converging
selection of CDR-H1 and CDR-L1 sequences (Table 2). In CDR-
H1 sequences, X-Asn-Tyr (X-N-Y) was selected in 7 of 8 cases,
where X was always a hydrophilic residue (Asp, Glu, Asn, Gln,
His, Lys, Arg; D, E, N, Q, H, K, R) or a glycine. In CDR-L1,
sequences were more heterogeneous. CDR1s of negative controls
exhibited a more random pattern. An amber stop codon (TAG,
coding for Stop or Gln) was found in the CDR-H1 of 4 out of 8
positive clones and in the CDR-L1 of 1 out of 8 positive clones and
was corrected to CAG by PCR.
Three clones (VC2.2.2, VC2.2.5 and VC2.1.5) were chosen for
further characterization, since they showed the strongest ELISA
signal. Protein-A purified fractions were further purified by size-
exclusion chromography and monomeric preparations were used
for BIAcore analysis. Dissociation constants of 22, 35 and 43 nM,
respectively, were measured in this analysis, an improvement
by almost 4-fold compared to the parental scFv VC2 (81 nM)
(Figure 3C and Table 3). VC2.2.2, which exhibited the lowest
Kd, was subsequently used for further analysis of blocking
capacity.
VC2.2.2 anti-VEGF-C scFv blocks binding of VEGF-C to
VEGF-R2 and VEGF-R3
BIAcore assay. Fully processed human VEGF-C (DNDC-
VEGF-C) exerts its action via binding to VEGF-R2 and VEGF-
R3 and binds the two receptors with affinities of 410 and 135 pM,
respectively [22]. Fusions of VEGF-R2 or VEGR-R3 with the
crystallizable fragment (Fc) of human IgG (VEGF-R2-Fc or
VEGF-R3-Fc) were bound to an anti-Fc coated BIAcore chip to
generate a homogenous receptor surface. DNDC-VEGF-C was
then passed over the receptor surface and binding occurred. In
both cases, the receptor surface was able to bind almost equimolar
amounts of VEGF-C (data not shown). To assess the neutralizing
capacity of VC2.2.2 scFv, DNDC-VEGF-C was preincubated with
different concentrations of VC2.2.2 scFv to allow for the formation
of the scFv-antigen complex, and this complex was then injected
on the receptor surface.
The binding of DNDC-VEGF-C to immobilized VEGF-R3
was dose-dependently inhibited by anti-VEGF-C scFv VC2.2.2
(Figure 4A), but not by the irrelevant control scFv directed against
glutathione-S-transferase (GST) (Figure 4B). With 900-fold
molar excess of VC2.2.2 scFv, an 86% reduction of response
was achieved.
Table 3. Comparison of the kinetic constants of the affinity
matured anti-VEGF-C scFvs.
scFv kon (1/Ms) koff (1/s) Kd (nM)
Kd improvement
relative to VC2
VC2 4.45610
4 3.58610
23 81 -
VC2.1.5 2.39610
4 1.02610
23 43 1.9
VC2.2.2 5.65610
4 1.22610
23 22 3.7
VC2.2.5 2.85610
4 1.00610
23 35 2.3
The kinetic constants were fitted from dilution series of monomeric scFv
preparations with BIAevaluation3.1 software using a 1:1 Langmuir binding
model.
doi:10.1371/journal.pone.0011941.t003
Figure 4. VC2.2.2 blocks binding of VEGF-C to VEGF-R2 and
VEGF-R3 as measured by SPR. VEGF-R3-Fc was bound to a CM5-
sensorchip coated with anti-human IgG antibody. 10 nM DNDC-VEGF-C
was then preincubated with a 9 to 900 times molar excess of (A) anti-
VEGF-C scFv or (B) control scFv and injected on the VEGF-R3-Fc surface
and the amount of binding of DNDC-VEGF-C was measured by SPR. (C)
VEGF-R2-Fc was bound to a CM5 sensorchip coated with anti-human
IgG antibody. 10 nM of DNDC-VEGF-C or VEGF-A with or without
preincubation together with anti-VEGF-C scFv were then injected on
the VEGF-R2 surface and bound VEGF-A or VEGF-C was measured by
SPR.
doi:10.1371/journal.pone.0011941.g004
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was also dose-dependently inhibited by injection of a mixture of
DNDC-VEGF-C preincubated for 30 minutes with anti-VEGF-C
scFv VC2.2.2 (Figure 4C). With 900-fold molar excess of VC2.2.2
scFv, an 81% reduction of response was achieved. Binding of
10 nM VEGF-A to VEGF-R2 resulted in a response comparable
to the binding of 10 nM DNDC-VEGF-C but was not blocked by
a 900-fold molar excess of anti-VEGF-C scFv VC2.2.2, demon-
strating the specificity of the anti-VEGF-C scFv (Figure 4C).
Competitive ELISA. The flow-based BIAcore VEGF-C
neutralization assay measures the neutralizing potency of the
VC2.2.2 anti-VEGF-C scFv only during a short time span, since
the scFv-bound VEGF-C had only a short lasting possibility (the
passage through the flow-cell requires seconds) to dissociate from
the scFv and to bind to the immobilized VEGF-R on the chip.
The equilibrium between dissociation from the scFv and
association to the VEGF-R might not be reached during the
passage through the flow cell. Therefore, we next used a
competitive ELISA to characterize the neutralization potency of
the anti-VEGF-C scFv over a longer time span.
We found that VC2.2.2 anti-VEGF-C scFv dose-dependently
blocked the binding of biotinylated DNDC-VEGF-C to immobi-
lized VEGF-R, while the anti-GST control scFv 3D6 did not block
this binding (Figure 5). Blocking of VEGF-R2 binding was more
efficient than blockage of VEGF-R3 binding, in agreement with
the findings in the BIAcore assay and the fact that affinity of
DNDC-VEGF-C to VEGF-R3 is higher than to VEGF-R2 [22].
With a 900-fold molar excess of VC2.2.2 anti-VEGF-C scFv,
binding of biotinylated DNDC-VEGF-C to VEGF-R2 was
inhibited by 95%61.0%, while the binding to VEGF-R3 was
blocked by 74%63.5%. Blocking reached a significance level of
p,0.05 (Student’s t-test) vs. 3D6 irrelevant control antibody for
VC2.2.2 anti-VEGF-C scFv concentrations $200 nM or 100-fold
molar excess over biotinylated VEGF-C.
VC2.2.2 anti-VEGF-C scFv binds to an epitope on
DNDC-VEGF-C implicated in VEGF receptor binding
To locate the epitope on DNDC-VEGF-C to which VC2.2.2
anti-VEGF-C scFv binds, a peptide microarray consisting of
overlapping 15-mer peptides spanning the whole DNDC-VEGF-C
aa sequence was used. Cy3-labelled VC2.2.2 scFv and Cy5-
labelled 3D6 scFv were allowed to competitively bind to the
peptide array. Upon scanning, the ratio of median signals from
Cy3 vs Cy5 channels were used to generate a list of peptides bound
by the respective scFvs.
P. pastoris-derived DNDC-VEGF-C, the positive control protein,
emerged as the top-hit from this scan, being bound more than 100
times stronger by the anti-VEGF-C scFv than by the irrelevant
scFv (Table 4). This validates the usefulness of the peptide-array.
Target peptides more strongly bound by the VC2.2.2 anti-VEGF-
C scFv vs. the irrelevant scFv 3D6 contained the sequence
FFKPPCVSVYRC (bound more than 22 times stronger by
VC2.2.2 than irrelevant control) as well as the C-terminal
sequence spanning SCRCMS to RQVHSIIRRHHHH (bound
more than 4 times stronger).
Interestingly, the FFKPPCVSVYRC sequence maps to the
region on VEGF-C that is most important for receptor binding to
VEGF-R2 and VEGF-R3 (Figure 6) [24] and contains Cys156,
the key-residue responsible for VEGF-R2 binding [25]. Impor-
tantly, DNDC-VEGF-D, which is not bound by VC2.2.2, features
two different residues in the FFKPPCVSVYRC region, which
might be responsible for the loss of binding (Figure 1). The C-
terminal sequence SCRCMS to RQVHSIIRRHHHHHH lies in
proximity to the loop 2 in the site 1 receptor binding interface of
VEGF-C (Figure 6) and binding of anti-VEGF-C to this region
could therefore also sterically hinder the binding of VEGF-C to its
receptors.
The variable heavy domain VH of VC2.2.2 is sufficient for
binding to VEGF-C
Bacterial supernatant from IPTG induced cultures expressing
VC2.2.2 VH-myc or a control VH-myc were checked by ELISA
for reactivity against DNDC-VEGF-C. Binding to DNDC-VEGF-
C could be observed, while no unspecific stickyness to alpha-2-
macroglobulin was seen (Figure 7). Detection with protein-A was
also successful, pointing to a generally correct folding of the VH,
since protein-A binds to a conformational epitope on the opposite
face of the former dimerization interface between VH and the
variable light domain VL [26].
Anti-VEGF-C scFvs contain hydrophilic camelid VHH-like
mutations in the VH:VL dimerization interface
Upon reexamination of the anti-VEGF-C scFv, mutations in the
framework region 2 (FR2) and adjacent regions of the heavy chain
could be identified. In VC2 and its daughter clone VC2.2.2,
residue 44 was mutated from glycine (as encoded in the ETH-2
Gold library) to glutamic acid (Table 2), by a purinic single
nucleotide mutation from GGG to GAG, making it more
hydrophilic. The FR2 region lies within the dimerization interface
of the VH and VL domains and loss of the VL domain leads to
resurfacing of hydrophobic residues within the former dimeriza-
tion interface and could lead to decreased solubility and enhanced
aggregation. The G44E substitution and other hydrophilic
substitutions in the FR2 region are therefore a hallmark of the
variable heavy domain VHH in camelid heavy chain antibodies,
naturally occurring immunoproteins devoid of light chains
[27,28]. VC1 contains a mutation in the FR2 region where the
hydrophobic leucine at position 45 is replaced by the less
hydrophobic proline, caused by a CTG to CCG transition
mutation (Table 2). L45 is also one of the typical residues altered
in camelid VHH, although the canonical residue there is the
hydrophilic arginine. However, the CGG arginine codon can only
Figure 5. VC2.2.2 blocks binding of VEGF-C to VEGF-R2 and
VEGF-R3 as measured by competitive ELISA. 2 nM biotinylated
DNDC-VEGF-C was preincubated with varying amounts of anti-VEGF-C
scFv or control scFv and added on a VEGF-R2 or VEGF-R3 coated
microtiter plate. Plotted datapoints are means from 4 replicates 6 SEM.
The datapoints were fitted to a sigmoidal dose-response curve model
using GraphPad Prism 4. Inhibition of VEGF-C binding by anti-VEGF-C
scFv reached significance vs the control scFv (*, p,0.05, Student’s t-
test) at molar excess of 1006 more anti-VEGF-C scFv vs VEGF-C. #:
p=0.067 for anti-VEGF-C/VEGF-R2 vs control at molar excess of 336
more anti-VEGF-C than VEGF-C.
doi:10.1371/journal.pone.0011941.g005
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purine transversion, but transversions are about an order of
magnitude less frequent than purinic (A/G) or pyrimidinic (C/T)
transitions [29,30]. For a single pyrimidinic transition, proline is
the most hydrophilic residue ‘‘reachable’’ from the leucine codon
CTG. VC3 contains a mutation in C-terminal end of CDR-2,
where the already hydrophilic lysine at position 64 is substituted by
the similarly hydrophilic glutamic acid, by a AAG to GAG
transition mutation (Table 2). VC4, which binds only to P. pastoris-
derived DNDC-VEGF-C but not to mammalian cell-derived
DNDC-VEGF-C does (outside CDR-3s) not deviate from the
amino acid sequence encoded in the library (Table 2).
Anti-VEGF-C scFv with camelid-like mutations show
unfavorable gel-filtration profiles, but the single VH is
partly stabilized
When analyzed on a Superdex 75 size-exclusion gel-filtration
column, the anti-VEGF-C scFvs VC1, VC2 and VC3 as well as
the VC2 daughter VC2.2.2 eluted with several peaks indicating
presence of dimers, multimers or higher aggregates, and the
monomeric peak at about 11 ml was markedly reduced when
compared to a control scFv. VC4, which does not contain any
deviation from the ETH-2 Gold library sequence but does only
bind to P. pastoris-derived DNDC-VEGF-C, showed a more
favorable elution profile. Several peaks with later elution time-
points were also present both in VC1 to VC3 and VC4, indicating
probable proteolytic products (Figure 8A–F).
As determined by SDS-PAGE and anti-myc immunoblot,
protein-A purified myc-tagged VC2.2.2 VH and anti-GST VH
both run at about 12 kDa (Figure 9A,B), although their molecular
masses are calculated from their primary amino acid sequences as
14.6 kDa. When subjected to size-exclusion gel-filtration, the
VC2.2.2 VH showed a major peak corresponding to the putative
VH monomer [31], eluting just after the 13.7 kDa marker
(Figure 9C), while the non-‘‘camelized’’ anti-GST VH showed
peaks corresponding to higher molecular weights (Figure 9D).
Discussion
In this study, we describe the development of function-blocking
monoclonal antibody fragments against human DNDC-VEGF-C.
The blocking capabilities were confirmed at the molecular level
using BIAcore and competitive ELISA. Antibody phage-display
was used to select 4 lead binders from the ETH-2 Gold antibody
phage display library. From these 4 binders, one was specific for an
epitope only present on P. pastoris-derived DNDC-VEGF-C, which
was used for selection, while the other 3 clones bound to an
epitope in the conserved region of DNDC-VEGF-C. Binding to
the His-tag could be excluded, since DNDC-VEGF-D, to which
the scFv are not binding, also contains a His-tag.
Via affinity maturation of clone VC2, daughter clones with up
to 4-fold improved affinity (22 nM, clone VC2.2.2) were obtained.
The affinities of these daughter clones are in the same range as
described for VD1, a function-blocking mouse IgG against human
DNDC-VEGF-D [8].
The blocking of both VEGF-C binding to VEGF-R2 and
VEGF-R3 indicates that the epitope for VC2.2.2 scFv on DNDC-
VEGF-C might be localized in a region that is important for
binding to both of the receptors. Indeed, data generated by the
epitope-mapping peptide array hint to a specific binding to the
VEGF receptor binding domain on DNDC-VEGF-C. Recently,
the three-dimensional crystal structure of DNDC-VEGF-C in
complex with one of its receptors, VEGF-R2, was solved by X-ray
diffraction [32]. The receptor binding domains of VEGF-C were
Table 4. Epitope mapping.
Peptide/Protein log2 ratio Stdev
aVEGF-C
Signal Stdev aVEGF-C SNR Stdev aGST Signal Stdev aGST SNR Stdev
DNDC-VEGF-C 6.26 0.19 8346 5844 11.4 5.0 202 79 2.9 1.1
DNDC-VEGF-C 6.18 0.12 8531 5797 25.8 30.0 213 78 3.5 2.1
TNTFFKPPCVSVYRC 5.98 0.03 51361 1256 112.7 9.5 917 48 16.9 5.5
FFKPPCVSVYRCGGC 4.50 0.12 45671 391 120.2 89.2 2114 184 46.4 17.6
SCRCMSKLDVYRQVH 4.29 0.17 34911 1322 332.6 215.7 1872 142 49.4 12.4
RQVHSIIRRHHHHHH 4.22 0.17 22414 1071 166.6 43.8 1302 86 34.8 6.4
VYRQVHSIIRRHHHH 3.69 0.03 32602 1576 63.8 29.1 2615 189 26.4 3.1
KLDVYRQVHSIIRRH 2.67 0.07 25280 2821 123.0 68.9 4041 269 64.3 14.5
PPCVSVYRCGGCCNS 2.13 0.05 1555 65 25.0 2.4 415 37 9.0 2.1
SFANHTSCRCMSKLD 1.58 0.12 1248 54 16.1 4.5 459 9 6.8 3.8
NHTSCRCMSKLDVYR 1.53 0.24 7390 1362 170.9 95.4 2577 126 58.3 26.9
VTISFANHTSCRCMS 1.24 0.11 2945 165 65.6 24.5 1272 18 31.9 3.7
human IgG 0.07 0.01 9348 531 41.3 7.5 8917 583 31.3 4.8
human IgG 0.03 0.06 9071 491 34.0 15.0 8833 423 27.3 9.3
mouse IgG 20.05 0.04 4873 474 24.4 11.2 4969 363 27.1 8.6
mouse IgG 20.05 0.01 4885 268 43.0 6.9 4994 310 32.1 5.5
CMSKLDVYRQVHSII 20.36 0.13 401 43 7.0 1.1 388 32 4.5 3.0
QCMNTSTSYLSKTLF 20.96 0.16 1183 81 15.8 5.8 2065 121 10.4 1.2
Values are arithmetic means and standard deviations from 3 subarrays. SNR: signal to noise ratio, log2 ratio are log2 (VC2.2.2 anti-VEGF-C/3D6 anti-GST).
All peptides that generated data with errors, SNRs ,2 in both channels and signal intensities #100 in both channels were filtered out.
Shown is a representative array from at least 3 replicates. Dye-swap arrays yielded similar results.
doi:10.1371/journal.pone.0011941.t004
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terminal helix on VEGF-C (Figure 4A). Site 1 is composed of the
N-terminal helix alpha1 (His113 – Thr129) and the loop L2
(Asn167 – Leu171). Site 2 consists of the loops L1 (Asp139 –
Pro155) and L3 (Ile188 – Pro196). Site 1 is provided by one
VEGF-C monomer, while site 2 comes from the antiparallel
second VEGF-C monomer [32] (Figure 4B). The receptor binding
domains to both VEGF-R2 and VEGF-R3 have also earlier been
analyzed by mutational analysis of VEGF-C and these data
correlate well with the structural results for VEGF-R2 [24]. The
VEGF-C sites and residues responsible for binding to VEGF-R3
are essentially the same as those making contact with VEGF-R2.
F151FKPPCVSVYRC162, the top-hit peptide from the epitope
scan, maps to loop L1 in site 2 and the presumed dimerization
interface of DNDC-VEGF-C. Loop L3 in site 2 and, when
dimerized, loop L2 and helix alpha1, that contain other important
residues for VEGF receptor binding are located in the spatial
vicinity of the putative epitope. Binding of VC2.2.2 anti-VEGF-C
scFv could therefore possibly interfere with dimerization of VEGF-
C and sterically hinder VEGF-C loops 1 and 3 from making
contacts to the receptor (Figure 6). Importantly, DNDC-VEGF-D,
which is not bound by VC2.2.2 scFv, features two different
residues in the FFKPPCVSVYRC region, which might be
responsible for the lack of cross-reactivity towards VEGF-D
(Figure 1).
The observation that the VH of VC2.2.2 is sufficient for binding
to VEGF-C is intriguing. It might explain why during affinity
maturation in the first round, similar advantageous sequences were
selected in CDR-H1, while in CDR-L1 no consensus could be
observed. The identification of mutations in all three scFv binding
to mammalian cell-derived DNDC-VEGF-C offers a possible
explanation for these observations. Transitional single nucleotide
mutations leading to the hydrophilic FR2 substitutions G44E in
VC2 (and its daughter clone VC2.2.2) and L45P in VC1 as well as
the CDR2 substitution K64E in VC3 obviously lead to a selection
advantage during the panning against DNDC-VEGF-C. It can be
speculated that DNDC-VEGF-C favors binding of small single VH
domains in contrast to paired Fvs, maybe due to the heavy
glycosylation that may obstruct access to proteinaceous epitopes.
Hints that VL and VH are not paired correctly in the scFvs come
from gel-filtration profiles of first and second generation anti-
VEGF-C scFvs. The first generation scFv VC1, VC2 and VC3,
that contain mutations and bind to mammalian cell-derived
DNDC-VEGF-C as well as the VC2 daughter clones all showed
unfavorable gel-filtration profiles with an enhanced ratio of scFv
multimers or aggregates vs. monomers, while the first generation
scFv VC4, that does not contain mutations and binds only to P.
pastoris-derived DNDC-VEGF-C, shows a more favorable gel-
filtration profile with the monomer as the most prominent peak
(Figure 8). The mutations could be the cause of the special binding
properties or an evolutionary adaptation of the scFv-coding gene
towards higher solubility of the expressed non-properly folded
scFv. Both would result in a selection advantage, either during
panning of the scFv-bearing phage or during growth of the
phagemid-bearing E.coli. Interestingly, camelid VHHs have been
reported to often bind to unusual and hidden protein epitopes, e.g.
clefts in enzymes. This has been attributed to their especially long
CDR3 loop, which protrudes and is able to insert itself into
concave epitopes [33–35]. In contrast, normal Fv paratopes are
flat or contain a cleft themselves and normally bind to flat or
convex epitopes. Interestingly, the FFKPPCSVYRC epitope
candidate emerging from the peptide scan lies partly buried in
the dimerization interface between the VEGF-C dimers.
It can be speculated that the scarcity of neutralizing antibodies
against VEGF-C, especially against the fully processed DNDC-
VEGF-C, may result from its low immunogenicity, since the
amino acid sequence is extremely conserved between different
species. For instance, murine DNDC-VEGF-C is identical to the
rat sequence and both are identical to the human sequence in 114
out of 116 amino acids (98%). In addition, the high degree of
glycosylation of DND-VEGF-C may further reduce its immuno-
genicity – as an example, it is known that non-glycosylated forms
of therapeutic proteins like GM-CSF [36] or IFN-beta [37] greatly
enhance their immunogenicity in humans.
Compared to other inhibitors of the VEGF-C – VEGF-R2/3
axis, an anti-VEGF-C antibody has the main benefit of specifically
blocking the action of VEGF-C. This is important, since the
VEGF/VEGF receptor interaction network is highly redundant.
VEGF receptor blockers, for instance, do only block the action of a
VEGF ligand on the targeted receptor, but not on other VEGF
receptors activated by the ligand. At the same time, they block all
interaction with the targeted receptor, indiscriminate of the VEGF
ligand. Soluble VEGF-receptors (VEGF-traps) on the other hand,
block all ligands that bind to them. This broad-spectrum inhibition
(which might be advantageous in cancer therapy) may have
impacts on other tissues, where VEGF ligand and receptor
expression also occurs. For instance, VEGF-D is also expressed by
Figure 6. Possible VC2.2.2 anti-DNDC-VEGF-C epitope-localization within or near the receptor-binding region on DNDC-VEGF-C. (A)
The VEGF-C residues contacting VEGF-R2 as reported in [32] are represented in yellow (N-terminal helix), red (loop 1), orange (loop 2) and brown
(loop 3). The two epitope stretches identified in the peptide scan are colored in blue. From epitope B, only SCRCMSKL is shown, the C-terminal end is
missing in the reported structure. Overlaps of epitope A (FFKPPCVSVYRC) and receptor-contacting residues in loop 1 are colored in purple. Residues
in loop 1 found to affect (B) VEGF-R2-binding or (C) VEGF-R3-binding by mutational analysis [24] are shown with the same colors as in (A). The
localization of the epitopes within the VEGF-C dimer is shown in (D) and their interference with the boxed interface of VEGF-R2 (cyan) is shown in (E),
with magnifications in ‘‘side’’ view (F) and ‘‘top view’’ (G). The pdb file 2X1X was used for the representation (www.pdb.org).
doi:10.1371/journal.pone.0011941.g006
Figure 7. The VC2.2.2 VH is sufficient to bind DNDC-VEGF-C.
Binding of the single VH-domain of VC2.2.2 to DNDC-VEGF-C and an
unrelated antigen (alpha-2-macroglobulin, a2MG) was tested by ELISA
using either anti-myc and anti-mouse HRP or protein-A-HRP as
detection compounds.
doi:10.1371/journal.pone.0011941.g007
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manner via VEGF-R3 [14]. Interference with the VEGF-D/
VEGF-R3 axis might therefore potentially affect bone regenera-
tion. Conversely, VEGF-C is expressed in osteoclasts, where it
enhances bone resorption in an autocrine manner via VEGF-R3
[38].
Taken together, we have selected a human antibody fragment
that (i) binds to the receptor-binding region of mature, fully
processed human VEGF-C (DNDC-VEGF-C) and (ii) is capable of
blocking the interaction of DNDC-VEGF-C with both VEGF-R2
and VEGF-R3 at the molecular level. The VH of the selected anti-
VEGF-C scFvs contain camelid VHH-like mutations and VC2.2.2
VH is sufficient to bind to DNDC-VEGF-C. Upon further
engineering of this minimal, 14.6 kDa antibody fragment to
enhance solubility and stability, it may serve as the basis for
development of bulkier fully human neutralizing anti-VEGF-C
immunoproteins with improved half-lives in circulation. Such
inhibitors could be useful in treatment of cancers that rely on
direct VEGF-C signaling such as Kaposi sarcoma [39], acute
myeloid or lymphocytic leukemia [40,41] and cancers that
metastasize via the lymphatic vasculature [42] but also against
cancers that have become refractory to anti-VEGF-A treatment.
Figure 8. SEC gel-filtration profiles of anti-VEGF-C scFvs. Protein-A purified scFv were injected on a Superdex 75 10/300 GL size-exclusion gel-
filtration column. Markers represent the major elution peaks of the molecular mass standards ovalbumin (43 kDa) and ribonuclease A (13.7 kDa).
doi:10.1371/journal.pone.0011941.g008
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VEGF-C-induced bone degeneration and age-related macular
degeneration.
Materials and Methods
Bacterial Media
Phage growth medium 2YT was mixed from 16 g tryptone
(Fluka, Buchs, Switzerland), 10 g yeast extract (Fluka) and 5 g
NaCl (Fluka) per liter. For growth of phage infected E.coli TG1 on
solid agar plates, 2YT was supplemented with 100 mg/ml
ampicillin (Sigma-Aldrich, Buchs Switzerland) and 1% (w/v)
glucose (Fluka) to give 2YTAG(1%) and mixed with 17 g of agar
(Ha ¨nseler, Herisau, Switzerland) per liter.
Plasmids
The pHEN1 plasmid was used for expression of scFv in E.coli as
described previously [19]. For expression of the VH domain, the
VH sequence was amplified from the VC2.2.2 scFv-encoding
pHEN1-based plasmid by PCR using the upstream forward
primer LMB3long (attaching 59 of the scFv coding sequence) and
the downstream reverse primer VHrev (annealing at the 39 end of
VH) (Table 5). The PCR product was then cut with NcoI and NotI
and ligated into pHEN1-backbone cut with the same enzymes.
The resulting plasmid encoding VC2.2.2 VH from Glu1 to Ser113
(Chothia 89–97 numbering scheme [43]) as well as the C-terminal
myc-tag and amber stop codon was subsequently checked by
sequencing.
Antigens
Human recombinant DNDC-VEGF-C was expressed from a
pPICZalpha based expression vector (Invitrogen, Paisly, UK) in
the yeast Pichia pastoris and contains an N-terminal His-tag
(Figure 1). Purification to homogeneity was accomplished by
IMAC affinity chromatography and gel filtration as described
previously [44]. Human recombinant DNDC-VEGF-C and
DNDC-VEGF-D, produced in mouse myeloma cells, were
purchased from R&D Systems (Abingdon, UK). Human VEGF-
A165 was kindly provided by the National Cancer Institute
(Bethesda, MD). Alpha-2-macroglobulin was purchased from
Sigma-Aldrich.
Biotinylation
DNDC-VEGF-C from P. pastoris or mammalian cells was
biotinylated with SS- or LC-NHS-Biotin (Pierce, Rockford, IL).
400 ml of a 500 mg/ml protein solution in PBS (Gibco) was mixed
Figure 9. SDS-PAGE and immunoblot analysis as well as SEC gel-filtration profiles of anti-VEGF-C VC2.2.2 VH and anti-GST VH.
Protein-A purified VH under non-reducing (nr) and reducing (red) conditions were separated by SDS-PAGE and (A) stained using Coomassie-Blue or
(B) immunoblotted using an anti-myc antibody followed by anti-mouse HRP. Protein-A purified (C) anti-VEGF-C VC2.2.2 VH or (D) anti-GST VH were
injected on a Superdex 75 10/300 GL size-exclusion gel-filtration column. Markers represent the major elution peaks of the molecular mass standards
ovalbumin (43 kDa) and ribonuclease A (13.7 kDa).
doi:10.1371/journal.pone.0011941.g009
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agent in MilliQ water and incubated for 1 hour at RT. For
removal of unreacted biotinylation agent, the mixture was loaded
on a PD10 gel filtration column (GE Healthcare, Glattbrugg,
Switzerland), topped up with 2.12 ml PBS, eluted with 3.5 ml PBS
and fractions of 0.5 ml were collected. The protein containing
fractions, as measured per spectrophotometric absorbance at
280 nm, were pooled.
To check the biotinylation of the protein, 100 mlo fp r o t e i n
solution in PBS was dotted on a nitrocellulose membrane (Biorad,
Hercules, CA) with an Easy-Titer dot-blot system (Pierce). After
drying for 15 min, the membrane was blocked for 1 hour
with 3% BSA (Fluka) in PBS at RT. Following washing with
PBS-0.1% Tween-20 (PBST), the biotinylated protein on the
membrane was detected with Streptavidin-HRP (GE Healthcare)
1:20000 in 3% BSA/PBS. The membrane was then again
washed three times for 5 min with PBST, incubated with ECL
(GE Healthcare) for 5 min and imaged using the GelDoc analysis
system (Biorad).
Library selections on immobilized antigen
The ETH-2-Gold antibody phage library [19] was used to pan
on fully processed DNDC-VEGF-C derived from Pichia pastoris.A
Maxisorp immunotube (Nunc, Wiesbaden, Germany) was coated
overnight at room temperature with 50 mm g/ml DNDC-VEGF-C
in 4 ml of 100 mM carbonate buffer, pH 9.6. As control, another
immunotube was incubated with carbonate buffer alone. The next
morning, immunotubes were rinsed three times with PBS and
blocked with 5 ml of 2% (w/v) of skimmed milk powder in PBS
(MPBS) for 2 h at room temperature. After rinsing three times
with PBS, ca 5610
12 transducing units (tu) of the phage library in
2% MPBS were added to the immunotubes. Subsequently, the
immunotubes were incubated on an orbital shaker for 30 min and
for another 90 min standing upright at room temperature.
Unbound phage was washed away with ten washes of PBST
and PBS each. For subsequent panning rounds, washing steps
were increased to twenty washes with each buffer. Bound phage
was eluted for 15 min by incubating the immunotubes on a rotator
with 1 ml of 100 mM glycine, pH 2.2, adjusted with HCl. After
collecting the eluate, the elution buffer was neutralized by adding
200 ml 1 M Tris-HCl pH 8.6. The eluted phage was subsequently
used to infect 10 ml of exponentially growing E.coli TG1 at
OD600=0.5 for 35 min at 37uC. Titration of the eluted phages,
phage amplification and colony picking were performed as
described previously [45].
Affinity selections with biotinylated antigen
For selection of affinity-matured binders from the affinity
maturation library, panning in solution with biotinylated antigen
was used. This was done to prevent selection of binders that bind
only to denatured VEGF-C. Up to 3 biopanning rounds with
different concentrations of biotinylated P. pastoris-derived DNDC-
VEGF-C (VC2.1 series; 1
st round with 3 nM, 30 nM and
300 nM; 2
nd round with 30 pM and 3 nM; 3
rd round with 30
pM) and biotinylated mammalian cell-derived DNDC-VEGF-C
(VC2.2 series; 1
st round with 300 pM, 3 nM and 30 nM; 2
nd
round with 3 nM) were performed. Prior to selection, 50 ml
streptavidin coated magnetic beads (M-280 Dynabeads, Dynal
Biotech, Oslo, Norway) per selection were blocked with 1 ml 3%
BSA in PBS for 1 hour at room temperature and resuspended in
50 ml 2% BSA/PBS. 1 ml of antibody phage library (approxi-
mately 10
12 tu in total) in 2% BSA/PBS was incubated with the
biotinylated antigen at the above stated concentrations for 1 hour
on a rotator at room temperature. The streptavidin magnetic
beads were then added to the phage/antigen mixture and allowed
to capture the biotinylated antigen and adhering phages for
15 min on a rotator at room temperature. Using a magnetic rack,
the beads were subsequently washed 7 times with 1 ml each of
PBS-Tween (1%) and 3 times with PBS. Then, the phages were
eluted from the magnetic beads with 100 ml of 100 mM glycine,
pH 2.2, adjusted with HCl, for 10 min at room temperature. The
phage-containing supernatant was then removed and neutralized
with 1 ml of 1 M Tris, pH 7.4. Infection of TG1 E.coli, titration
and amplification was performed as described above.
ELISA screening
After 2 and 3 rounds of panning, individual bacterial colonies
containing the phagemid were picked and inoculated into 150 ml
2YTAG(0.1%) and grown for 3 hours in a 37uC shaking
incubator. Then, the cells were induced by addition of 50 mlo f
2YTA containing 4 mM isopropyl-thio-galactopyranoside (IPTG;
Applichem, Darmstadt, Germany), to give a final concentration of
1 mM IPTG, and grown overnight for 30uC.
A 96-well maxisorp plate (Nunc) was coated overnight at RT
with 50 mg/ml of DNDC-VEGF-C in PBS as described above.
The next day, the ELISA plate was washed three times with PBS
Table 5. Primers used in this study.
Primer Sequence (59–39) Reference
LMB3long CAGGAAACAGCTATGACCATGATTAC [19]
fdseqlong GACGTTAGTAAATGAATTTTCTGTATGAGG [19]
VHrev GAGATGAGTTTTTGTTCTGCGGCCGCactcgagacggtgaccagggt (NotI site underlined,
annealing site to VH in lowercase)
This study
DP47CDR1ba TGGGTCCGCCAGGCTCCAG [23]
DP47CDR1for AGCCTGGCGGACCCAGCTCATMNNMNNMNNGCTAAAGGTGAATCCAGAGGCTGC [23]
DPL16CDR1ba TGGTACCAGCAGAAGCCAGGA [46]
DPL16CDR1for TCCTGGCTTCTGCTGGTACCAGCTTGCMNNMNNMNNTCTGAGGCTGTCTCCTTG [46]
VC2.2.2heavybackmutfo AGCCTGGCGGACCCAGCTCATATAATTCTGGCTAAAGGTGAATCCAGAGGCTGC This study
VC2.2.3lightbackmutfo TCCTGGCTTCTGCTGGTACCAGCTTGCAGTATTCTGTCTGAGGCTGTCTCCTTG This study
VC2.2.13heavybackmutfo AGCCTGGCGGACCCAGCTCATCAACGACTGGCTAAAGGTGAATCCAGAGGCTGC This study
M = A/C, N=A/C/G/T.
doi:10.1371/journal.pone.0011941.t005
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was then washed again three times with PBS and each well was
supplemented with 20 ml of 10% MPBS containing a 1:200
dilution of mouse anti-myc 9E10 antibody (Sigma, Cat No
M5546) and 1:200 dilution of anti-mouse horseradish peroxidase
labelled sheep antibody (GE Healthcare) as secondary reagents.
The bacterial supernatant was centrifuged for 10 min at 1800 g
and 80 ml of supernatant from each well was added to the
corresponding ELISA well. The plate was then incubated for
1 hour at RT on an orbital shaker. After three washes each with
PBST and PBS using a squirt bottle, 100 ml Blue-POD peroxidase
substrate (Roche, Mannheim, Germany) was added to each well
and the chromogenic reaction was stopped with 50 ml1MH 2SO4
after 10 min. The plates were then read with a spectrometer at
450 nm and 650 nm. To screen for false positives, the superna-
tants were also tested on maxisorp plates coated with PBS alone.
Since DNDC-VEGF-C derived from P. pastoris was used for the
panning, the supernatants were also tested on streptawell plates
(Roche) coated with 100 ml1 0
27 M biotinylated DNDC-VEGF-C
derived from mammalian cells (R&D Systems) in PBS overnight at
4uC.
SPR analysis
All solutions to be injected into the BIAcore 3000 (GE
Healthcare) were filtered using a 0.22 mm filter (Millipore, Zug,
Switzerland). A streptavidin-coated sensorchip flowcell (GE
Healthcare) was coated at a flowrate of 5 ml/min with 25 mlo f
100 nM biotinylated DNDC VEGF-C derived from either P.
pastoris or mammalian cells in PBS, 0.01% azide, 0.005%
Surfactant P-20 (GE Healthcare). For both antigens, a stable
immobilization level of more than 2000 RU was achieved. Surface
regeneration was done by injection of 5–10 ml 10 mM HCl.
Positive supernatants from the ELISA were filtered through a
0.22 mm filter and injected as is.
Affinity maturation
Parental antibodies obtained after 3 rounds of panning were
randomized in the CDR1 at the following positions (numbering
according to the Chothia 89–97 scheme [43]): 31, 32, 33 for VH,
31, 31a, 32 for VL-kappa and 31a, 31b and 32 for VL-lambda
using degenerate primers DP47CDR1for, DPK22CDR1for and
DPL16CDR1for respectively, together with DP47CDR1ba,
DPK22CDR1ba, DPL16CDR1ba, LMB3long and fdseqlong
respectively (Table 5). The three amplicons were assembled by
PCR assembly essentially as described [19]. All primers were
purchased from Sigma.
Affinity matured clones that contained a TAG amber stop
codon in the mutated CDRs (coding for glutamine in suppressor
strains and stop in non-suppressor strains), were backmutated to
CAG by using PCR backmutation primers as specified in Table 5
and essentially the same assembly procedure as described above.
Expression and purification of scFv antibody fragments
An overnight starter culture of 2YTAG(5%) inoculated with a
single colony of phagemid bearing E.coli TG1 was diluted 1:100 in
1 l of 2YTAG(0.1%) and grown at 37uC, 225 rpm until
OD600=0.5. The cells were then induced by addition of IPTG
(final concentration 1 mM) and grown overnight at 30uC, 225
rpm. Bacterial supernatants were clarified by centrifugation at
5000 g, 4uC for 45 min and filtered through a 0.2 mm filter (TPP,
Trasadingen, Switzerland). Supernatants were then loaded on a
protein-A affinity column (Biorad) using the Profinia automated
protein purification system (Biorad), according to the manufac-
turer’s recommendations. The columns were washed with Buffer
A (100 mM NaCl, 0.1% Tween-20 (Sigma), 0.5 mM EDTA
(Sigma) in PBS) and subsequently Buffer B (500 mM NaCl,
0.5 mM EDTA in PBS). Bound scFv were then eluted with
100 mM triethylamine (Sigma) and immediately neutralized in 1
M Tris-HCl, ph 7.0. The eluate was dialyzed overnight against
PBS using Spectra/Por dialysis tubing with 12–14 kDa cutoff
(Spectrum Labs, Breda, The Netherlands) and concentrated to
about 1 mg/ml with Amicon Ultra 15 ultrafiltration devices with
10 kDa cutoff (Millipore). For sterilization, the scFv preparation
was finally filtered through a 0.22 mm filter (Pall, Basel,
Switzerland).
SDS-PAGE and immunoblotting
Proteins were resolved on 4–12% gradient bis-tris Novex
precast gels in MOPS running buffer, using LDS loading buffer
with or without reducing agent as indicated by the manufacturer
(all components from Invitrogen). Precision Plus molecular weight
standards were from Biorad. Staining of SDS-PAGE gels was
accomplished using Bio-Safe Coomassie (Biorad). For immuno-
blotting, the proteins resolved with SDS-PAGE were transferred to
nitrocellulose membranes (Biorad). Membranes were subsequently
blocked for 2 h with 5% skimmed milk powder (Coop, Basel,
Switzerland) in phosphate buffered saline (PBS, Gibco) containing
0.1% (v/v) Tween-20 (Sigma), referred to as MPBST. Immuno-
blotting was performed using mouse anti-myc 9E10 antibody
(1:1,000, Sigma) and secondary anti-mouse HRP-labeled sheep
antibody (1:20,000, GE Healthcare), diluted in MPBST. Bands
were revealed using ECL Plus detection reagent (GE Healthcare).
Size-exclusion chromatography
Size-exclusion chromatography (SEC) and isolation of mono-
meric scFv was performed on an A ¨kta FPLC system using the
Superdex 75 10/300 GL column (GE Healthcare) at a flow of
0.5 ml/min. The column was calibrated with molecular mass
standards ovalbumin (43 kDa) and ribonuclease A (13.7 kDa) (GE
Healthcare).
Epitope mapping using peptide array
A peptide array (PepStar; JPT, Berlin, Germany) was used to
map the epitope of the anti-VEGF-C antibody. The amino acid
sequence spanning human DNDC-VEGF-C from T103 to R227
and an appended C-terminal 6xHis-tag was used to define 40
overlapping, consecutive 15-mer peptides with 3 residues shift
each. Synthesis of the peptides, using SPOT peptide synthesis, and
peptide printing on glass slides were conducted at JPT. The myc-
tag-epitope AEQLISEEDL, human and murine IgGs as well as P.
pastoris-derived DNDC-VEGF-C were printed as additional
controls. Each slide features 3 identical subarrays, corresponding
to 3 technical replicates per condition.
ScFvs for epitope mapping were fluorescently labelled using
Cy3 and Cy5 monoreactive dye (GE Healthcare). Dye aliquots
were prepared by dissolving monoreactive Cy3 or Cy5 dye,
intended for labeling of 1 mg protein, in 10 ml of DMSO, dividing
into 1 ml aliquots and vacuum-drying in a speed-vac. Dye aliquots
were stored at 4uC in an desiccator under vacuum in the dark.
20 ml of 1 M sodium bicarbonate buffer, pH 9, was added to
200 ml of a 1 mg/ml scFv solution in PBS to bring the final pH
between 8.5 and 9.5. Then, this solution was added to 2 aliquots of
Cy3 or Cy5 monoreactive dye and left to incubate for 1 hour at
room temperature. Non-reacted dye was subsequently quenched
with 100 ml Tris buffered saline (TBS), pH 7.5. To separate free
dye from the scFv-bound dye and to exchange the buffer to PBS,
the solution was loaded on a microcon concentrator column YM-
10 (Millipore) with a membrane-cutoff of 10 kDa. The concen-
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times at 14 krpm for 30 min and washed with 500 ml PBS between
spins. Finally, the dye-labelled scFv was resuspended in 200 ml
PBS and the protein concentration as well as the dye absorption
was measured using a spectrophotometer (Nanodrop; Thermo
Scientific, Wilmington, DE).
Arrays were competitively incubated essentially according to the
manufacturer’s instructions in a sandwich-like fashion with a Cy3-
labelled anti-VEGF-C scFv and a Cy5-labelled irrelevant scFv at
30 mg/ml each, in 300 ml 0.22 mm filtered binding buffer (TBS
containing 3% FBS and 0.5% Tween-20) at 4uC overnight in a
humid atmosphere in the dark. Then, the microrarrays were
washed 3 times for 6 min with binding buffer and 3 times for
6 min with MilliQ water in the dark. Slides were dried by spinning
for 2 min at 300 rpm and scanned using a Genepix 4200A scanner
(Axon Instruments, MDS Analytical Technologies, Concord, ON,
Canada) with photo-multiplier tube (PMT) gain values for both
channels set to prevent saturated pixels and to yield a pixel-count
ratio of 1:1 for the two channels. Scanning was done using 2 line
averaging and a resolution of 5 mm. Gal-file grids were manually
adjusted observing both colors and Cy3/Cy5 ratios were
normalized to human and murine IgG as non-specific controls.
VEGF-C neutralization assay using BIAcore
Unless otherwise stated, all reagents were from GE Healthcare.
A CM5 sensorchip equilibrated overnight with HBS-P was
activated by injection of two times 70 ml 1:1 EDC/NHS mixture
at a flow rate of 5 ml/min, resulting in a DRU of 214. Then, 68 ml
of monoclonal anti-Fc antibody at 25 mg/ml diluted in 10 mM
sodium acetate pH 5.0 immobilization buffer was injected. After
5 min, 50 ml ethanolamine was injected to deactivate the
remaining binding sites. A stable immobilization level of about
16000 RU was achieved. Surface regeneration between cycles was
done by injection of 5 mlo f3MM g 2Cl2. Injections on the anti-Fc
coated CM5 chip were done at a flowrate of 5 ml/min and the
different proteins were diluted in HBS-P buffer. For VEGF-C/
VEGF-R3 binding experiments, 100 ml of 100 nM VEGF-R3-Fc
recombinant protein (R&D Systems), resulting in a response of
about 2500 RU were immobilized on the anti-Fc coated CM5
chip. For VEGF-C/VEGF-R2 binding experiments, 100 mlo f
100 nM VEGF-R2-Fc recombinant protein (R&D Systems),
resulting in a response of about 1200 RU were immobilized on
the anti-Fc coated CM5 chip.
VEGF-C neutralization assay using competitive ELISA
A maxisorp plate was coated in quadruplicate with 100 mlo f
2 mg/ml monoclonal mouse anti-human IgG (Chemicon, Temes-
cula, CA) in PBS overnight at room temperature. The next
morning, the plate was washed 3 times with PBS and blocked for
2 hours at room temperature with 200 ml blocking buffer (3% BSA
(Probumin; Millipore) in PBS). The plate was then washed again 3
times with PBS and incubated with 100 ml1mg/ml VEGF-R2-Fc
or VEGF-R3-Fc in blocking buffer for 2 hours at room
temperature. After washing with 3 times PBS, 100 ml of a mixture
of 2 nM biotinylated P. pastoris-derived DNDC-VEGF-C preincu-
bated for 30 min with a variable concentration of VC2.2.2 anti-
VEGF-C scFv or irrelevant scFv in blocking buffer was added to
the ELISA plate for 1 hour at room temperature. Subsequently,
the ELISA plate was washed for 2 times with PBST and 1 time
with PBS and a mixture of streptavidin-horseradish peroxidase
conjugate diluted 1:1000 in blocking buffer was added and
incubated for 1 hour at room temperature. Finally, the plate was
washed again 3 times with PBST and 3 times with PBS and
developed as detailed above.
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